Non-carbapenemUTIβ-Lactam/β-lactamase inhibitorThis systematic review was conducted to compare the efficacy of non-carbapenem 尾-lactam/尾-lactamase inhibitors (BLBLIs) versus carbapenems for the treatment of urinary tract infections (UTIs) caused by extended-spectrum 尾-lactamase-producing ...
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated ... V Celeste,H Jose,A Nishaal - 《Drug Design Development & Therapy》 被引量: 9发表: 2016年 Ceftazidime–avibactam: novel antimicrobial combi...
We gave intravenous infusions of sulbactam, a beta-lactamase inhibitor, in combination with ampicillin or cephalothin to women 2 days after cesarean section delivery. The elimination t1/2 was 1.0 hours, the volume of distribution at stea... G Foulds,RD Miller,AK Knirsch,... - 《Clinical Pha...
A non-beta-lactam antibiotic inhibitor for enterohemorrhagic Escherichia coli O104:H4Dynamic simulationβ-LactamaseE. coliO104: H4Non-β-lactam inhibitorThe overuse of antibiotics has caused an increased prevalence of drug-resistant bacteria. Bacterial resistance in E. coliis regulated via production ...
The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci, 8(ll):2330-2337, Nov 1999.Powers, R. A., Blazquez, J., Weston, G. S., Morosini, M. I., Baquero, F., and Shoichet, B. K. (1999) The complexed structure and ...
The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC _beta- lactamase. Protein Sci 1999; 8 : 2330-7.Powers, R. A.; Blazquez, J.; Weston, G. S.; Morosini, M. I.; Baquero, F.; et al. The complexed structure and antimicrobial activity of a non...
beta-LactamaseE. coli O104: H4Non-beta-lactam inhibitorThe overuse of antibiotics has caused an increased prevalence of drug-resistant bacteria. Bacterial resistance in E. coli is regulated via production of beta-lactam-hydrolyzing beta-lactamases enzymes. Escherichia coli O104: H4 is a multi-...
beta-lactam-beta-lactamase inhibitors (BLIs) have previously demonstrated antimicrobial activity against Acinetobacter baumannii (AB). Colistin retains the highest susceptibility rate against A. baumannii, and has demonstrated synergy with other antimicrobials, including beta-lactam-BLIs. Therefore, we ...
beta-lactamase inhibitorenzymesstructure-based virtual screeningmolecular dockingantibioticsBackground: There is an urgent need to develop novel inhibitors against clinically widespread extended-spectrum beta-lactamases (ESBLs) to meet the challenges of the ever-evolving threat of antibiotic resistances. Most...